CRVS

NASD Corvus Pharmaceuticals, Inc.
Oct 7, 2026 · 6:37 AM ET LAST TRADE Market Closed

$10.59 ↑ +0.03 (+0.28%) Trading Up from the previous close of $10.56

YTD change
+37.53%
vs 20-day SMA
-12.72%
vs 200-day SMA
-25.33%

Price ranges

Previous day
$10.20 $10.96
open $10.75 close $10.56
-$0.19 (-1.77%)
Today
$0.00 $0.00
$10.59
Past week
$10.20 $12.03
from $11.76 now $10.59
-$1.17 (-9.95%)
Past month
$10.20 $13.93
from $13.93 now $10.59
-$3.34 (-23.98%)
This year
$6.39 $26.95
from $7.70 now $10.59
+$2.89 (+37.53%)

Price & Performance

-3.79 (-26.41%) / 6M

$9.98$12.80$15.61$18.43Apr 7Jul 8Oct 6

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good
  • The stock is 60.7% away from all-time highs of $26.95
  • CRVS is up 38% since the beginning of the year
  • CRVS is up 54% over the past 12 months
  • CRVS is down 24% over the past 1 month
  • 23% of all CRVS investors are betting against CRVS

CRVS reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is +53.7%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.19
Earnings momentum +1.1% Quarterly EPS growth
Quarterly change +1.1%

Valuation

P/E ratio N/A
Enterprise value $760.9M
Beta 2.25

Balance sheet & scale

IncomeN/A
RevenueN/A
Cash$215.2M
Debt$728.0
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $890.8M

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $402.60 -0.09%
MRNA Moderna, Inc. $187.46 -7.75%
RVMD Revolution Medicines, Inc. $199.87 -3.76%
ROIV Roivant Sciences Ltd. $35.53 -0.70%
BNTX BioNTech SE Sponsored ADR $95.73 -1.96%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.